Press release
T-Cell Immunotherapy Pipeline - Key Players Analysis Novartis, Celllular Biomedicine Group, Kite Pharma
The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer. It is gaining huge traction globally, for its several advantages over conventional therapies such as very low or no side effects and high specificity.
Browse report sample at: https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis/report-sample
*Strategic collaborations for the development of T-cell immunotherapeutic
The research finds that the different companies are collaborating for the development of T-cell immunotherapeutic. In June 2015, Celgene Corporation and Juno Therapeutics, Inc. collaborated for the development and commercialization of immunotherapies.
Some of the key players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine Group, Inc., Kite Pharmaceuticals Inc. and others.
Browse report at: https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis
*Chimeric antigen receptors (CAR) T-cell is majorly researched and developed, representing 75% T-cell immunotherapeutic candidates
CAR T-cells are the modified T-cells used to express CARs, which recognize specific antigens present on targeted cell. CARs are specifically designed synthetic receptors, linked with the single-chain variable fragment (scFV) of a monoclonal antibody. The domain includes T-cell receptor CD3-zeta chain, which graft specificity into an immune effector cell. It mediates T-cell cytotoxicity and activation when bound to a target cell.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=t-cell-immunotherapy-pipeline-analysis
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release T-Cell Immunotherapy Pipeline - Key Players Analysis Novartis, Celllular Biomedicine Group, Kite Pharma here
News-ID: 1433596 • Views: …
More Releases from P&S Intelligence
Remote Access Provided by Cloud Category Fuels Call Center AI Market
In 2021, the call center AI market generated sales worth $1,982.9 million, and it is expected to contribute $12,910.6 million in 2030, progressing at a rate of 23.1% from 2021 to 2030, ascribed to the growing up requirements for improved data analytics to manage customer inquiries with the real-time response to improve customer engagement through social media.
In order to pace up the 4th industrial revolution, businesses across various industries…
Growing Demand for CSM System Will Drive the Customer Engagement Solutions Marke …
The total value of the customer engagement solutions market was $18,186.8 million in 2021, and it will rise at a growth rate of above 10% in the near future, to reach $43,398.9 million by 2030. The major reasons behind the growth of this industry are growing usage of such solutions in serval industries like healthcare, telecommunications, BFSI and FMCG.
North America will grow the fastest with a rate of 10.5% in…
Reduced Operational Cost of Energy Efficient Motors Propels Motion Control Marke …
The motion control market generated a revenue of $14,887.5 million in 2021, and it is expected to contribute $23,286.4 million in 2030, progressing at a rate of 5.1% from 2021 to 2030, ascribed to the rising demand for industrial robots and integration of components with the motion control systems for convenient use.
Moreover, the evolving motion control standards and protocols propel the market, for example, the OPC UA TSN protocol controls…
North America, the Largest Revenue Producer in Public Safety and Security Market
The size of the public safety and security market was at $411 billion in the year 2021, which will reach over $1,115 billion by the year 2030, advancing at a growth rate of around 12% in the years to come. This is largely ascribed to the rising application of innovative technologies in smart cities, increasing crime rates, the increasing cases of disastrous accidents, and the growing count of terrorist activities…
More Releases for Novartis
Oncology Drugs Market Competitive Outlook - GlaxoSmithKline, Novartis, Merck
"The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types. The pharmaceutical industry develops drugs to…
Rydapt Market 2020 Clinical Analysis – Novartis
Global Rydapt Market Growth 2020-2025
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Rydapt Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought…
Gleevec Market Overall Study Report 2020-2027 | Novartis
Gleevec Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Gleevec market between 2020 and 2027. In terms of value, the Gleevec industry is expected to register a steady CAGR during the forecast period.
The report offers a systematic presentation of the existing trends,…
Rydapt Market Demand & Competitive Analysis by 2025| Novartis
Market Research Report Store offers a latest published report on Rydapt Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth…
Global HER2-negative breast cancer Treatment Market to 2025| AstraZeneca, Bristo …
Researchmoz added Most up-to-date research on "Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2019-2025" to its huge collection of research reports.
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
In 2018, the global HER2-negative breast cancer Treatment…
Nilotinib Market Report 2018 – 2023: Novartis
The Study Paper in this Global Nilotinib Market includes Novartis.
Get Free Sample Brochure of Nilotinib Market spread across [142 pages] @ https://www.marketgrowthinsight.com/sample/4896
Unbiased perspective on intangible aspects such as key challenges, threats, new entrants as well as strengths and weaknesses of the prominent vendors too are…
